GlassScriptPhysician profile
Amanda Quarles
NPI 1699084020
$8,513.72
in general payments reported to CMS, 2019-2025
49 companies · $934 in 2025
The $934 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,836 · 2022: $3,075 · 2023: $1,520 · 2024: $149 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $694.32 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $537.18 | 2021-2025 | |
| Abbvie INC. | $422.18 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $410.09 | 2021-2022 | |
| Amgen INC. | $398.83 | 2021-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $392.40 | 2021-2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $361.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $345.61 | 2021-2023 | Ponvory |
| Biogen, INC. | $318.84 | 2021-2025 | Vumerity |
| Teva Pharmaceuticals USA, INC. | $300.10 | 2021-2025 | Ajovy, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $297.67 | 2021-2025 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $293.61 | 2021 | |
| Horizon Therapeutics Plc | $265.11 | 2021-2023 | Uplizna |
| Genzyme Corporation | $248.13 | 2021-2025 | |
| Lundbeck LLC | $234.98 | 2021-2025 | Vyepti |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $228.93 | 2021-2025 | Mavenclad |
| Eisai INC. | $225.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $214.26 | 2021-2025 | |
| Pfizer INC. | $208.76 | 2023-2025 | |
| Celgene Corporation | $186.14 | 2022-2024 | Zeposia |
| Tg Therapeutics, INC. | $169.37 | 2022-2025 | |
| Kyowa Kirin, INC. | $163.03 | 2021-2023 | Nourianz |
| Neurocrine Biosciences, INC. | $158.71 | 2021-2023 | Ongentys, Ingrezza |
| Acorda Therapeutics, INC | $155.89 | 2021-2023 | Inbrija |
| Ucb, INC. | $151.50 | 2021-2025 | Nayzilam, Fintepla |
| Amylyx Pharmaceuticals, INC. | $143.80 | 2023 | Relyvrio |
| Ani Pharmaceuticals, INC. | $117.86 | 2023-2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $91.00 | 2021 | |
| Inspire Medical Systems, INC. | $82.07 | 2023 | Inspire |
| Otsuka America Pharmaceutical, INC. | $80.95 | 2023 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $62.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $58.12 | 2021-2025 | Wainua |
| Medtronic, INC. | $51.64 | 2021-2025 | Linq II |
| Lilly USA, LLC | $49.20 | 2021-2022 | |
| Mdd US Operations, LLC | $48.69 | 2022-2023 | Xadago, Apokyn |
| Alnylam Pharmaceuticals INC. | $48.04 | 2021-2023 | Onpattro |
| Axsome Therapeutics, INC. | $43.15 | 2025 | Symbravo |
| Jazz Pharmaceuticals INC. | $40.89 | 2025 | |
| Csl Behring | $35.38 | 2022 | |
| Ns Pharma, INC. | $31.02 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $22.70 | 2021 | |
| Merz Pharmaceuticals, LLC | $17.80 | 2022 | |
| Argenx US, INC. | $17.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.92 | 2021 | |
| Ge Healthcare | $16.63 | 2022 | |
| Neurelis, INC. | $16.28 | 2023 | Valtoco |
| Sumitomo Pharma America, INC. | $15.31 | 2023 | Aptiom |
| Piramal Critical Care | $12.66 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Quarles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.